表面的生物功能化,以最大限度地减少心血管辅助设备的不良影响
Rosa Correa Leoncio de Sa1,2, Aron Jose Pazin de Andrade2, Vagner Roberto Antunes3
1Laboratory Associated of Materials and Sensors, National Institute for Space Research - INPE, Sao Paulo, Brazil.
Artificial organs
|November 29, 2023
概括
纹理表面的钻石样碳 (DLC) 涂层提高了心室辅助器件的生物相容性. 较厚的DLC涂层 (TSB) 有效地抑制了生物材料的粘附和磨损,这对长期设备性能至关重要.
科学领域:
- 生物材料科学 生物材料科学
- 医疗设备工程 医疗设备工程
- 表面化学 表面化学
背景情况:
- 血液与非内皮表面的反应性对长期的心室辅助器件 (VAD) 开发构成挑战.
- 纯虽然是惰性的,但不会阻止血栓生成反应,因此需要进行表面修改.
研究的目的:
- 为了评估激光诱导周期性表面结构的有效性,然后在表面上使用不同厚度的钻石样碳 (DLC) 涂层.
- 为定制VAD应用程序的可湿性概况和改善血红相容性.
主要方法:
- 测试了四种表面:纯 (RM),纹理 (TS),0.3μm DLC (TSA) 的纹理和2.4μm DLC (TSB) 的纹理.
- 植入物被放置在Wistar大鼠的腹部大动脉中,并在没有抗凝剂的情况下在12周内评估血液动力相互作用.
主要成果:
- 在与大动脉壁接触的表面上观察到内皮组织封装.
- TSB植入物证明了生物材料粘附,磨损磨损和分层的抑制.
- 伪新极端层被异质地确定,在测试表面的度更高.
结论:
- 纹理表面的钻石样碳 (DLC) 涂层显著提高了血红相容性.
- 较厚的DLC涂层 (2.4μm) 在防止生物粘附和材料降解方面优越,这表明长期改善VAD性能的潜力.
相关概念视频
Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...


